Please assess the completion status of the following clinical trial:

Trial Title: A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients that have signed informed consent and are \>/= 40 years of age.~* Patients with stable COPD according to GOLD 2011.~* Patients with a post-bronchodilator FEV1 of \>/= 30% and \< 80% predicted and a post-bronchodilator FEV1/FVC \<0.70.~* Current or ex-smokers who have a smoking history of at least 10 pack years.~* Patients with an mMRC grade 2 or greater.~Exclusion Criteria:~* Patients with Type I or uncontrolled Type II diabetes - Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (\>450 ms for males and females) and confirmed by a central assessor. (These patients should not be re-screened.)~* Patients who have a clinically significant ECG abnormality at Visit 101 or Visit 102. (These patients should not be re-screened.)~* Patients with a history of malignancy of any organ system, treated or untreated, within the last five years.~* Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention.~* Patients who had a COPD exacerbation within 6 weeks prior to screening.~* Patients who have a respiratory tract infection within 4 weeks prior to screening.~* Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.~* Patients with a history of asthma. 8. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to age 40 years.~* Patients with a blood eosinophil count of greater than 600 mm/3 during run-in.~* Patients with concomitant pulmonary disease.~* Patients with a diagnosis of alpha-1 anti-trypsin deficiency.~* Patients with active pulmonary tuberculosis.~* Patients in the active phase of a pulmonary rehabilitation programme.~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 (Type: EXPERIMENTAL): 27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
- QAB149 (Type: ACTIVE_COMPARATOR): 27.5 ug b.i.d.
- NVA237 (Type: ACTIVE_COMPARATOR): 12.5 ug b.i.d.
- Placebo (Type: PLACEBO_COMPARATOR): b.i.d

Based on this trial design, predict the completion outcome and termination type (if applicable).